| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.054 | 0.8 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | -0.043 | 0.8 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |